Both of this week’s stories land on one theme: the gap between what’s marketed and what’s actually proven, or legally settled.
A UCLA-led review put a number on the evidence gap
Researchers at UCLA’s David Geffen School of Medicine, led by Dr. Thomas Kremen, reviewed 565 studies on six popular peptides: BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. [UCLA Health, Sep 2026]
More than two-thirds of studies were animal-only; human research was generally small, weakly controlled and in some cases carried undisclosed conflicts of interest, particularly for BPC-157. For musculoskeletal uses, the review found essentially no studies showing significant clinical benefit.
The safety findings are worth reading twice
- A halted trial. An MK-677 trial stopped early after higher rates of congestive heart failure.
- A firsthand account. Dr. Kremen described a patient hospitalized with dangerously low cardiac output after taking peptides.
- Contamination risk. Products outside FDA manufacturing oversight can contain heavy metals like arsenic or lead.
Lilly’s two-front legal war over retatrutide
Front one: Lilly vs. the FDA. In September 2025 a federal judge ruled the FDA acted arbitrarily in deciding retatrutide wasn’t a “biological product.” Its backbone is 39 amino acids, one short of the agency’s 40 threshold. Lilly appealed to the Seventh Circuit, arguing for biologic status; oral arguments are set for September 24, 2026. [Compound Protocol; Reason, Sep 10, 2026]
It matters: biologics get 12 years of exclusivity instead of 5, and are permanently excluded from compounding exemptions. If retatrutide is a biologic, it could never be legally compounded.
Front two: Lilly vs. sellers. In August, Lilly filed six federal lawsuits against Legendary Peptides, Lone Star Peptide, Texas Peptides, Astra Peptides, a med spa (Aesthetic Envy) and a compounding pharmacy (Striker Pharmacy), under state consumer-protection and unfair-competition law. [Frier Levitt, 2026]
Where the compounding review stands
Unchanged: the six-peptide recommendation still sits with HHS. Removal from the “Category 2” list isn’t the same as being legal to compound; it only opens the door to rulemaking.
Why this matters if you’re considering peptide therapy
- Physician-guided only, never self-selected from a research-chemical website.
- Licensed U.S. pharmacies, never the kind of sellers named in Lilly’s lawsuits.
- Evidence over hype. Care plans follow real clinical data.
FAQ
What did the UCLA review find?
Most of 565 studies on six peptides were animal-only, human research was low quality, and there was little to no evidence of musculoskeletal benefit, plus documented safety concerns.
Is retatrutide legal to buy?
No. It’s in Phase 3 trials and not FDA-approved for any use.
Is retatrutide a drug or a biologic?
Unresolved. The Seventh Circuit hears Lilly’s appeal on September 24, 2026.
Does this affect currently available treatments?
Not directly. Semaglutide and tirzepatide remain FDA-approved prescription drugs.
This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.
Sources
- UCLA Newsroom — With peptide supplements, marketing outpaces the medicine
- Compound Protocol — Is Retatrutide a Biologic?
- Reason — Can a new weight loss treatment escape the regulatory thicket?
- Frier Levitt — Lilly Retatrutide Lawsuits Target RUO Peptide Sellers
- Endpoints News — Lilly appeals retatrutide classification ruling